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Abstract
Introduction
This study aims to investigate the comparisons in dynamic conformal arc, VMAT (no ASC),
forced MU limitations (ASC), or a 50/50 hybrid arc (ASC) in how they can improve a lung
SBRT case where the tumor is abutting a dose critical structure. The goal of this research is to
investigate multiple treatment techniques in an attempt to increase the dose constraint pass rate.
The variables in comparison are how well different plan iterations can successfully meet
constraints as well as pass a 0.5 modulation complexity score (MCS).

Methods
10 previously treated patients were used in this study who exhibited tumors abutting the heart,
great vessels, bronchus, brachial plexus, rib, and the spinal cord. All of these patients were
planned in all 5 iterations. Each of the plan consisted of two partial arcs and the patient specific
iterations were compared with the same gantry arcs.

Results
The dynamic conformal arc plan exhibited the highest MCS, however it also was unable to pass
any of the constraints. The VMAT plan iteration failed the MCS parameter on every patient,
however more plans were able to meet the dose constraints. With an introduction of a x1 MU
forced limitation, x1.5MU forced limitation, and a 50/50 hybrid, MCS as well as dose constraint
pass rate significantly improved. The 50/50 hybrid iteration exhibited the most plans that passed
both of the constraint variables. This treatment method incorporates the dose conformality of a
dynamic conformal arc with the dose painting abilities of a VMAT arc. The ASC that was
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applied to these beams prevents the beam from becoming overly modulated which would result
in an increase in MU and an increase in low dose to the patient.

Conclusion
This study has been able to determine that a 50/50 hybrid technique or a VMAT (ASC) with a
forced MU limitation can be considered a reliable and reproducible alternative for treating lung
SBRT cases that abut a dose limiting organ.

Keywords: SBRT, Hybrid planning, MCS score, MU Evaluation, VMAT

Introduction
Cancer treatments come with a plethora of options depending on the specified cancer
diagnosis and location. Within the past decade alone, the number of advances made in radiation
oncology has been astonishing. With the first Stereotactic Body Radiation Therapy (SBRT) lung
trials taking place in 1995, SBRT has become the standard in lung treatment ever since (Onishi,
Araki. 2011). SBRT offers benefits such as decreased days of treatments, submillimeter
treatment accuracy, and rapidly modulating multi-leaf collimators (MLCs) to achieve better
conformality. Despite the many advancements already made, radiation oncology staff are
constantly working towards giving the best possible treatments to their patients.
SBRT is defined by the American College of Radiology (ACR) as the use of very large
doses of radiation (>5000-6000 cGy) over a duration of ≤5 fractions. Some characteristics of
SBRT include the use of multiple beam angles (≥10 beams with one to two arcs) to better attain a
conformal dose distribution to the target (Przybysz, Bradley. 2017). With SBRT being a
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hypofractionated approach to radiation therapy, it results in a greater daily dose which in turn
results in the patient experiencing less days of receiving treatment. In order to be qualified for an
SBRT lung treatment, patients must present with an inoperable lung tumor that is smaller than 5
cm in diameter (Przybysz, Bradley. 2017). Once it exceeds the 5 cm cutoff, a SBRT treatment is
no longer considered. This is due to the percentage of lungs receiving such a high dose of
radiation at once.
To date, the treatment of choice in patients unable to endure surgery is SBRT
(Timmerman, Herman, Cho. 2014). In recent years, the biggest advancement in SBRT has been
safety. A benefit that you get with a SBRT plan is the option to alter beam configurations. The
beam configurations are dependent on the tumor orientation, size, and the patient’s anatomy. If
the planner is trying to avoid a dose critical structure like the heart or the remainder of the lung,
the angle of the gantry as well as the MLCs can be strategically altered so that the plan reflects
that. With a 3D conformal arc plan, you can alter the beam gantry as well as the MLCs, but
without the modulating of the MLCs with the beam on, it could result in an increased dose to the
surrounding organs.
With surgery being the gold standard in treating early stage lung cancers, the desire to
push for treatment advancements for inoperable lung cancers was there. The history of SBRT
came from the use of treating cranial masses with SRS treatments for 40 years before attempting
to treat extracranial. Due to rapid advances in radiation treatment delivery equipment in the
1990’s, stereotactic radiation methods were trialed for lung cancer in 1995 (Onishi, Araki. 2011).
The CHISEL trial was the first randomized SBRT trial for inoperable stage 1 NSCLC patients.
The 101 patients in the study were either given the SBRT treatment of 5400 cGy for 3 fractions
and the conventional radiation therapy patients received either 6600 cGy in 33 fractions or 5000
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cGy in 20 fractions (Haridass. 2018). The results of this study proved that there is superiority in
patient outcome between the two treatments.
The problem with treating lung tumors with SBRT is finding the best way to treat the
tumor as well as pass the predetermined constraints. Tumor motion and potential for tumor
growth are of the utmost concern when introducing large amounts of modulation in a treatment
plan. Studies have shown that more than 50% of NSCLC move more than 5mm during treatment
according to 4D CT scans (Chang.2015). While the attempt of increasing the PTV margin could
be sufficient, that still leaves room for error for patients who exhibit more than 5mm of
movement. This poses an even greater risk of treating surrounding OARs. A potential
workaround could be to utilize a deep inspiration breath hold (DIBH) treatment. However, in a
patient with a diseased lung this could be exceedingly difficult due to breathing changes and
inability to hold their breath.
Aside from that, when more MLCs enter the primary beam and less of the prescribed
dose is making its way to the target, the monitor units (MU) will increase to make up for that loss
of coverage, resulting in an increase of radiation to the surrounding organs at risk (OAR). The
goal of this research is to investigate multiple treatment techniques in an attempt to increase the
dose constraint pass rate. The methods to be compared are a dynamic conformal arc, VMAT
without aperture shape controller (ASC), utilizing a forced MU limitation, and a 50/50 hybrid.
With an over modulated beam resulting in an increase in low dose and an increase in MU, these
metrics will be compared by viewing the modulation complexity score (Varian Medical Systems,
Palo Alto, Ca, USA) (MCS) in conjunction with their constraint pass rate. Using an ASC to limit
complexity to the MLCs, the introduction of a modulation complexity score (MCS) is to quantify
the amount of modulation in a plan. A MCS is the measurement of the position of the MLCs, the
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degrees of irregularity in the shield shape, how much weight the segment receives, and the area
(McNiven, Sharpe, Purdie, 2010). These factors combined create the MCS factor and turn it into
a numerical value. The MCS is scored within a range of 0 to 1 where the closer to 0 the number
falls, it represents a greater uncertainty (Jubbier, 2021).
With the higher degree of complexity that comes with VMAT plans, there is a greater
dependence on the accuracy of MLC leaf positioning. Research shows in some cases using
apertures with a width of 0.5 cm, the max dose was underestimated by about 20% (Younge,
Matuszak, Moran, McShan. 2012). Due to this major overdose, research was conducted to try to
minimize this. Edge penalty is an aperture metric designed to penalize complex MLC aperture
shapes based on the size and ratio that is designated to a given area. After the study was
performed, it found that in cases with edge penalty, yielded plans more regularly shaped MLC
patterns and had plans with 30% less MU compared to the same plans without edge penalty
(Younge, Matuszak, Moran, McShan. 2012). These results are beneficial because it shows a
linear correlation that an increase in complex MLC patterns also increases the MU output. In an
attempt to decrease MLC complexity, Varian issued an aperture shape controller (ASC) (Varian
Medical Systems, Palo Alto, Ca, USA). The ASC was introduced in Eclipse in version 15.5 and
when turned on very high, it favors apertures of minimal local curvature (Scaggion, Fusella,
Agnello, 2019). This allows the optimizer to favor plans that are less modulated and easier to
treat. Previous work has indicated that using the aperture shape controller combined with an MU
objective can significantly reduce MLC complexity. For this reason, the two VMAT plans that
had ASC set to very high also had an MU objective limit with a priority of 99. The MU limit
value was based on the total MU of the patient’s conformal 3D arc plan. One iteration had an
MU objective equal to the total MU of the conformal 3D arc plan (1xMU) and the other iteration
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had an MU objective that allowed for a 50% increase to the total MU of the conformal 3D arc
plan (1.5xMU) (Scaggion, Fusella, Agnello, 2019).
According to physicist Jing Cai, Ph.D. (2014), the complexity of a SBRT plan is not
worth the minimal dosemetric benefit that it has over a 3D plan. Some things that aren’t taken
into consideration are the planning, quality assurance of each step, imaging, delivery, and
reproducibility. When all of these things are taken into consideration, the benefits of a 3D plan
increase as it has less steps as well as guarantee coverage to the tumor. In the same
Point/Counterpoint article, physicist Harish K. Malhotra disagrees with the points made by Cai,
stating how difficult it is to treat a centrally located tumor with 3D arcs. This conversational
piece helps introduce the idea of a hybrid SBRT/3D plan as they both have their own strengths
and weaknesses.
This study will investigate multiple treatments to compare dynamic conformal, a forced
MU limit, and a hybrid which will help to determine if an alternative iteration can succeed in
having an improved dose conformity and MCS value. Each plan will be challenged by abutting
dose limiting OARs to compare the plan’s ability to effectively cover the tumor while sparing
normal tissue. The goal of this study will be to determine if a hybrid beam plan can be
considered a valuable alternative in creating conformal low modulation SBRT lung cases.

Methods
To conduct this study, there have been 10 patients who have had their imaging
anonymized and their previous plans wiped while still having their original contours. All of these
patients were previously treated with lung SBRT treatments. The patients vary due to their
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location of the tumor in their lungs and what surrounding structures they neighbor against. These
patients consist of two abudding the heart and the great vessels, two abudding the bronchus, two
abudding the brachial plexus, two abudding the rib, one abudding the spinal cord and bronchus,
and one abudding the spinal cord and great vessels. All of the listed patients will be treated in the
following techniques: 100% 3D Conformal, 100% VMAT (no ASC), 50/50 hybrid (ASC), 100%
VMAT x1 MU(ASC), and 100% VMAT x1.5 MU (ASC). Prior to formulating the treatment plan
of action, all relevant institutional review boards (IRB) have been contacted in order to gain
approval prior to moving forward. The initial IRB application was sent through The Northshore
University HealthSystem IRB due to this being the institution the research was being conducted
within. After the research was approved and all requirement documents were submitted, all of
the information was forwarded to the University IRB for a second approval. After the research
was approved and documented by the University IRB as well, the research was able to begin.
The imaging that the treatment plans were created off of are representations of imaging
during simulation. The simulation results in setting a patient up in the treatment position and
acquiring computed tomography (CT) images resulting in 2mm thick slices. While the previous
contours have been imported to the anonymous patient again, to assure a quality check, they
have been checked again by a staff medical dosimetrist and staff medical physicist. All of the
plans will be formulated on a Trilogy IX (Varian Medical Systems, Palo Alto, Ca, USA)
treatment machine. The energy used on all plans will be 6X-SRS. We have decided to go with
6X-SRS due to research showing that when used, beams present with better target conformity,
lower intermediate dose spilling, as well as a decreased OAR dose (Pokhrel, Halfman, Stanford.
2019). The Radiation Oncologist deems what should be drawn as an ITV. An ITV is useful in
lung treatments as it accounts for tumor movement while breathing. To the ITV there will then

8

Shawn Loutos
be a 0.5 cm expansion around the volume to create the PTV. For the 3D conformal part of the
plans, there will be a PTV expansion of 0.2 cm in all directions as well as a 0.4 cm expansion
superiorly and inferiorly to create the block. With the 3D conformal plans, the MLCs were fit to
the block without any expansion, resulting in an increased margin to the volume. In the VMAT
plans, the plans were made to the PTV expansion volume with a 0.5 cm margin using the arc
geometry tool.
Each plan was created using two fully coplanar partial arcs to minimize contralateral lung
dose. The arc degree angles between the different iterations of each patient specific plan were all
kept the same to achieve the best results possible. The most appropriate collimator angle
(somewhere between 20-30 degrees) was used as seen fit for each patient plan and was kept the
same for each percentage iteration of the plan. When a new field was inserted into each plan,
new MLCs were selected to each field and fit to the previously created block by a margin of 0.00
centimeters with the optimize collimator jaw function turned on.
The patients were selected for this study due to them all being previously treated SBRT
patients with a tumor that closely abuts a dose limiting structure. For the plans that this research
conducts, the dose planned will be 1000 cGy for 5 fractions prescribed to the planning target
volume (PTV). With the heart, great vessels, bronchus, brachial plexus, rib, and spinal cord
being the OAR at risk, their dose limits need to be considered. At our institution, the constraints
that are followed for 5 fractionation lung SBRT cases are based on RTOG 0813 (Bezjak, Bradley,
Gaspar, 2009). These constraints are listed on Table 1. For the purposes of this research, a failing
chest wall constraint was deemed acceptable due to lack of PTV coverage or plan quality; a
failing chest wall constraint was ignored.
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In order for the calculations to take place, the algorithm Acuros_XB_15606 (Varian
Medical Systems, Palo Alto, Ca, USA) was used in Eclipse treatment planning system (version
15.5, Varian Medical Systems, Palo Alto, Ca, USA). Every field will present a SRS arc treatment
technique which will result in a 0.1 grid size resolution resulting in greater resolution. The target
volume for each plan is set to the PTV with an optimization objective of 100% of the volume
receiving 95% of the prescription dose. While the PTV is set as the dose objective, the ITV goal
is to receive 100% of the target volume to receive 100% of the dose prescription. Having the
MLCs fit to the block ensured a complete coverage to the PTV. Due to there not being a need for
MLC optimization in the 3D conformal plan, calculating and assessing a DVH and Clearcheck
(Varian Medical Systems, Palo Alto, Ca, USA) is the next step in this process.
With there being tight constraints on structures that are abutting tumors receiving a dose
beyond what their constraint allowed, the next step was to convert doses into structures, crop out
what was outside of the designated structure, and attempt to meet the constraints as closely as
possible while still achieving a 100 @ 95 PTV. Multiple iterations of this was completed until the
100% 3D conformal arc plan was as good as it could be while still obtaining PTV coverage. For
each respective x1 MU or x1.5 MU iteration, the total MU from a patient’s 3D conformal was
added and either multiplied by 1 or by 1.5 to get the maximum MU for the optimizer. The
subsequent MU value was then used as an MU limit within the optimizer and set at a 99 priority.
This is designed to force a comparable MU to the 3D plan, which the optimizer will attempt to
achieve. After as many optimizations deemed necessary, these iterations were considered
complete when all of the constraints were either passing or they were pushed to an extent where
passing was deemed impossible
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The goal of the hybrid plans is to incorporate the dose conformity of a dynamic arc and
the dose sparing of a VMAT arc. The initial 3D plan was used and copied over in order to make
the hybrid plans. The first arc was kept the same and the second arc was replaced with a VMAT
arc with the opposite rotating gantry angles and collimator rotation, fit to the PTV. To adjust the
percentage of 3D vs VMAT in a plan, the daily dose was adjusted. Due to the starting
prescription plan being 1000 cGy for 5 fractions resulting in 5000 cGy, in the 50/50 plan it was
adjusted to 2500 cGy for 5 fractions in 2500 cGy per 3D and VMAT plan, resulting in a plan sum
total dose still receiving 5000 cGy. The initial 3D MU was multiplied by 0.5 and the product of
that multiplication is then multiplied by 1.5 in order to receive the max MU output for the VMAT
aspect of the plan. In the optimizer, the MU objective is turned on and the product is entered as
the max MU with a strength of 99.
In each case, the 3D conformal plan was made first and the altered and desired VMAT
MU was based on the MU that the 100% 3D conformal plan produced. The hybrid plans
incorporated the factor of the VMAT optimizer. In the optimizer, the PTV was set to a lower and
an upper dose in every plan. The lower was set at 100% of the volume receiving 5000 cGy and
the upper was set at 0% of the volume receiving 6250 cGy, both being set to a priority of 125.
Due to each hybrid plan iteration not being set to a prescribed dose of 5000 cGy, a base plan was
inserted in the optimizer. Because of this, the 3D part of each hybrid plan had to be made first in
order to be inserted as a base dose in the optimizer. This tells the optimizer that the PTV already
received 50% of the 5000 cGy in the optimizer and the VMAT part of the hybrid plan completes
the rest of the dose. After the optimization, a plan sum is created from the two parts of each
hybrid plan and the plan is assessed in the plan sum. When the plan sum achieved a passing plan,
a total plan was created by forcing the MU that the plan sum put out so that all of the arcs are
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under the same one plan. The hybrid plans were considered complete when all of the constraints
were either passing or they were pushed to an extent where passing was deemed impossible.
After each optimization, each plan was normalized so that 100% of the prescription dose
covered 95% of the PTV. Hot spots were deemed accessible at 135% or below. While rings were
not utilized to create these plans due to some conflicting constraints, other constraints were
included in the clear check template to confirm conformality in each plan. From RTOG 0813, the
PTV has a conformity index 100% (CI) ≤ 1.2-1.5 deemed as passing. Another CI constraint is
CI 50% 4.347 - 5.347. The third conformity constraint in place is used in conjunction with a
2cm contour. This contour was created by copying the external contour and cropping 2 cm from
the PTV. The constraint states “MaxDT using PTV_5000 volume ≤ ” 57.063 - 66.829%. Due to
all of these plans being created on previously treated patients, none of the created plans went
through a QA process.
To perform the data analysis, a graphical representation was done to document what plans
were passing or failing the constraint list. In addition to this, the plans were sent to Radformation
(Varian Medical Systems, Palo Alto, Ca, USA) to receive a MCS score that was reported back.
Our institution deemed a MCS score ≥ 0.50 as passing.

Results
With the 3D conformal plans being the first to be created in each of the 10 patients, that
plan was used as a baseline in regards to any MU or failing constraints. Table 2 is a table analysis
briefly discussing each individual 3D conformal and VMAT plan (Patient 1-10) in their ability to
pass the predetermined constraints. This table achieves this by listing the structures that are
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unable to pass on a given plan alongside the constraint goal. The failing constraints are displayed
in red and the passing constraints are displayed in green. The passing constraints are not
respective of a lowest achievable value, rather as a passing constraint value that we did not try to
further decrease once passing was achieved.
The value of the MCS score to determine the plan deliverability and reproducibility was
introduced. Figure 1 shows the MCS score for the 3D and the VMAT plan iterations along with
their respective values. This figure proves that between the 3D and VMAT plans, the MCS
between the two iterations is vastly different and opens up the conversation for an alternative
plan. Figure 2 introduces the various forced MU VMAT plans (x 1 MU and x 1.5 MU) as well as
the 50/50 hybrid MCS values. This figure is split into 10 sections each resembling a given
patient. Each given patient presents 5 bars to signify a plan iteration specific MCS value.
Figure 3 compares the MU of a plan, the MCS of a plan, and the plan iteration. This
scatterplot presents the combined average of the MCS and MU for each individual plan to
convey a relationship between the MCS and the MU. To better determine this interaction, Figure
4 includes the MU / MCS point intersection of each plan. These results yield vastly different
results and compute an inverse correlation between the MCS and the MU. Based on the results
the scatterplots convey, MCS increases as MU decreases.
Table 3 compares each patient and their plan iteration to better visualize their MCS
passing status. A green “Pass” box represents a plan with a MCS value ≥ 0.5 and a red “Fail”
box represents a plan with a MCS value < 0.5. The sum of percentages of each plan iteration
column can be found in the final row signifying the pass rate of the MCS for each plan specific
type. These results suggest that the dynamic conformal arc, x1 MU, as well as the 50/50 hybrid
all have 100% success rate in achieving a passing MCS value of 0.5 or more. The VMAT
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iteration succeeded in 10% of the plans passing and the x1.5 MU succeeded in 60% of the plans
passing.
With the new plan iterations exceeding the initial VMAT plan MCS values, their ability
to pass constraints are to be taken into consideration. Table 4 has rows that list the patients from
Patient 1-10 in ascending order and columns that signify plan iteration. In addition to the
previous list of constraints that were attainable with the 3D and the VMAT plans, this adds the
constraint success rate of the forced MU limit and hybrid plan iterations, marking a green “Pass”
for plans that every constraint was met and a red “Fail” where plan iterations fail one or more
constraints. Table 5 lists the constraints that the forced MU and the hybrid plans were not able to
meet.
In an attempt to find the most optimal plan iteration that passes dose constraints and the
set MCS value, a combined table was made to present this. Table 6 reviews both the MCS and
passing constraint variables to illustrate plans that pass both. Plan iterations that achieve a ≥ 0.5
MCS as well as are successful in passing the dose constraints are marked with a green “Pass”.
Plans that were either unable to achieve the MCS value, dose constraints, or weren’t able to pass
either are marked with a red “Fail.” The sum of percentages of each plan iteration column can be
found in the final row signifying the pass rate based on the combination of dose constraints and
MCS.

Discussion
The results from comparing Conformal Arc, VMAT, VMAT with varying degrees of MU
limitation, and 50/50 Hybrid Arcs demonstrated that normal tissue dose constraints can be met
while adhering to modulation complexity constraints for Lung SBRT cases. Since the literature
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indicates that the over modulation of lung SBRT cases can lead to a significant deviation in
target coverage, particularly for targets with large internal motion, an effort should be made to
limit the modulation complexity for any such cases (Younge, Matuszak, Moran, McShan. 2012).
In regard to the performance of each planning method based on the constraint pass rate
and MCS values, the 50/50 hybrid shows clear benefits. Each of the hybrid plan iterations
succeeded in attaining a higher and passing MCS value in comparison to the VMAT plans as
well as they were better at passing the constraints in comparison to the 3D plans. This was not
surprising as a combination of dosepainting with VMAT as well as the improved conformity of a
dynamic arc can be combined while adhering to the modulation limitations. The benefit of this is
to be able to incorporate all aspects to make a viable plan for a lung SBRT case where the tumor
is abudding a dose critical structure. Hybrid SBRT iterations show clear benefits in regards to
better plan conformality, decreased plan complexity, as well as a better correlation between the
planned and the delivered dose (Liu, Sintay, Pearman. 2018).
Table 2 exhibits the difference of constraint pass rates between the dynamic arc and the
VMAT arc where there is a failing constraint on every patient for the dynamic arc iterations. The
VMAT plans all succeeded in passing the predetermined constraints. Due to the volume of PTV
overlapping the bronchus in Patient 3, we deemed that the VMAT plans would all pass due to
there being a physical limitation to meet the desired constraint without underdosing the PTV.
This resulted in all VMAT plans meeting or exceeding the desired constraints.
An attempt to compare the two extremes of dynamic arc and VMAT proved to exhibit a
great difference in MCS. Figure 1 presents the MCS comparison between dynamic conformal arc
and VMAT. The data suggests that while the VMAT was able to pass every possible constraint,
all of the plans were too highly modulated to be considered reproducible or deliverable. These
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results suggest that VMAT without the ASC is an inferior method when attempting to get a
passing MCS in comparison as a MCS ≥ 0.5 was unachievable on every VMAT plan with an
average total of 0.376. The introduction of a forced MU and a hybrid option helped bridge the
gaps between these two extremes on Figure 2. The average MCS of both the x1MU iteration and
the 50/50 hybrid resulted in 0.669 and the average of the x1.5MU iteration resulted in 0.521.
Figure 3 introduces a correlation between MU and MCS. In every patient iteration the
VMAT exhibited the highest amount of MU and the lowest MCS value. On the other end of this,
the dynamic arc always exhibited the lowest amount of MU and the highest MCS value. This
suggests that there is an indirect correlation between MU and MCS value. This correlation is
presented additionally in Figure 4. The forced MU and hybrid plans appear to counteract this and
produce more deliverable and reproducible plans due to exhibiting a lower MU and a higher
MCS. There is value in this correlation as having a more modulated beam not only increases
MU, but having a less modulated beam allows for a more reproducible plan (Younge, Matuszak,
Moran, McShan. 2012). This is extremely detrimental especially on a lung treatment where the
target can exhibit different breathing patterns day by day resulting in a geometric miss.
In regards to creating the most beneficial plan for the patient, both the MCS and dose
constraint pass rate are to be taken into consideration. Table 6 combines the pass rate of the two
variables to combine into a more absolute table. These results convey that 0% of the 3D
conformal plans in this study were able to pass both variables when abutting a dose limiting
structure. VMAT with no ASC succeeded in passing both of the constraints 10% of the time. The
forced MU limit plans both improved with 60% of the plans passing. The most advantageous
method in the treatment process was the 50/50 hybrid as 80% of the plans were able to succeed
in passing the constraints when paired next to a dose limiting structure. While adhering to a MCS
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value doesn’t limit the ability of an opposing iteration to produce a high quality plan, the
reproducibility of the plan day to day is what warrants the need to have a plan with a higher
MCS value.
Based on this research, we have found that by utilizing various optimization techniques
as well as 3D/VMAT hybrid planning, it was possible to significantly limit the modulation
complexity of each plan far beyond that of a standard VMAT plan as well as presenting an
increase in passing constraints. Future work will need to be done to determine if a specific
threshold for modulation complexity based on tumor size and motion can be derived, thereby
clearly defining a modulation complexity constraint to accompany any normal tissue dose
constraints. In addition, future work will need to be done to test different degrees of hybrid
iterations. As the percentage of dynamic conformal arc is increased in a hybrid plan, this would
result in even lower MU and treatment uncertainty (Liu, Sintay, Pearman. 2018).

Conclusion
This study investigated planning a lung SBRT case with a 3D dynamic conformal arc,
VMAT, forced MU limitations, or a 50/50 hybrid plan to determine if meeting the predetermined
constraints as well as meeting the MCS limit was attainable on alternate iterations. Based on this
research, the results suggest that utilizing a forced MU in the optimizer as well as utilizing a
50/50 hybrid plan are both viable options in an attempt to increase the MCS score and help in
meeting constraints. An attempt to utilize a less modulated beam in the future results in a
decrease in MU and therefore low dose spread to the patient as well as a more guaranteed tumor
coverage. In conclusion, setting an MU limit as well as utilizing a hybrid plan can be considered
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a more reproducible and more beneficial alternative for treatment planning of lung SBRT cases
where the tumor is abudding a dose critical structure. Clinics can use this research to make a
decision regarding a treatment method if there is a concern of tumor motion as the hybrid plan
has shown the ability to minimize modulation for dose constraints on abutting structures. Future
work will need to be done to determine if a specific threshold for modulation complexity based
on tumor size and motion can be derived. This would clearly define a MCS constraint to
accompany any normal tissue dose constraints.
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Table 1. RTOG 0183 Constraints

22

Shawn Loutos
Table 2. Normal Tissue Constraints and Values for 3D vs. VMAT

Table 3. Pass / Fail MCS
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Table 4. Constraint Pass Rate

Table 5. Normal Tissue Constraints and Values for x1MU vs x1.5 MU vs 50/50 Hybrid
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Table 6. MCS and Constraint Pass Rate Combined

Fig. 1. Bar Graph of 3D vs. VMAT MCS values
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Fig. 2. Bar Graph of all Plan Iteration MCS Values
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Fig. 3. Scatterplot of the Average MCS and MU Per Plan Iteration

Fig. 4. Scatterplot of all MCS and MU values Per Plan
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